A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide In Subjects with Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets with Insulin Therapy

Grants and Contracts Details

StatusFinished
Effective start/end date8/20/03 → 4/30/06

Funding

  • Amylin Pharmaceuticals Inc: $33,285.00